These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7562928)

  • 1. Chiral dioxolane inhibitors of leukotriene biosynthesis: structure-activity relationships and syntheses using asymmetric dihydroxylation.
    Crawley GC; Briggs MT
    J Med Chem; 1995 Sep; 38(20):3951-6. PubMed ID: 7562928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
    Crawley GC; Dowell RI; Edwards PN; Foster SJ; McMillan RM; Walker ER; Waterson D; Bird TG; Bruneau P; Giroaeau JM
    J Med Chem; 1992 Jul; 35(14):2600-9. PubMed ID: 1321908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
    Hutchinson JH; Riendeau D; Brideau C; Chan C; Falgueyret JP; Guay J; Jones TR; Lépine C; Macdonald D; McFarlane CS
    J Med Chem; 1994 Apr; 37(8):1153-64. PubMed ID: 8164257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-acylaminophenol derivatives as novel lipoxygenase inhibitors: synthesis and inhibitory effect on 5-lipoxygenase and leukotriene B4 production.
    Kikuchi M; Hashimura Y; Tsuzurahara K; Nagasawa M; Inoue H; Taniguchi T; Uchida T
    Biol Pharm Bull; 1994 Aug; 17(8):1038-46. PubMed ID: 7820104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
    Biochem Pharmacol; 1994 Jul; 48(1):31-9. PubMed ID: 8043028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 5-lipoxygenase inhibitors ZD2138 and ZM230487 are potent and selective inhibitors of several antigen-induced guinea-pig pulmonary responses.
    Kusner EJ; Buckner CK; Dea DM; DeHaas CJ; Marks RL; Krell RD
    Eur J Pharmacol; 1994 May; 257(3):285-92. PubMed ID: 7522174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
    Lau CK; Bélanger PC; Dufresne C; Scheigetz J; Therien M; Fitzsimmons B; Young RN; Ford-Hutchinson AW; Riendeau D; Denis D
    J Med Chem; 1992 Apr; 35(7):1299-318. PubMed ID: 1313879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model.
    Raychaudhuri A; Chertock H; Chovan J; Jones LS; Kimble EF; Kowalski TJ; Peppard J; White DH; Satoh Y; Roland D
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Apr; 355(4):470-4. PubMed ID: 9109363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C.
    Hawthorne AB; Boughton-Smith NK; Whittle BJ; Hawkey CJ
    Gut; 1992 Apr; 33(4):513-7. PubMed ID: 1316305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
    Tateson JE; Randall RW; Reynolds CH; Jackson WP; Bhattacherjee P; Salmon JA; Garland LG
    Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Methoxy-2-methyltetrahydropyrans: chiral leukotriene biosynthesis inhibitors, related to ICI D2138, which display enantioselectivity.
    Crawley GC; Briggs MT; Dowell RI; Edwards PN; Hamilton PM; Kingston JF; Oldham K; Waterson D; Whalley DP
    J Med Chem; 1993 Jan; 36(2):295-6. PubMed ID: 8380872
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis of 1,5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4 formation.
    Ergün BC; Nuñez MT; Labeaga L; Ledo F; Darlington J; Bain G; Cakir B; Banoglu E
    Arzneimittelforschung; 2010; 60(8):497-505. PubMed ID: 20863006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
    Hutchinson JH; Riendeau D; Brideau C; Chan C; Delorme D; Denis D; Falgueyret JP; Fortin R; Guay J; Hamel P
    J Med Chem; 1993 Sep; 36(19):2771-87. PubMed ID: 8410991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
    Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
    Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
    Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA
    J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
    Ducharme Y; Brideau C; Dubé D; Chan CC; Falgueyret JP; Gillard JW; Guay J; Hutchinson JH; McFarlane CS; Riendeau D
    J Med Chem; 1994 Feb; 37(4):512-8. PubMed ID: 8120869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase.
    Mano T; Stevens RW; Ando K; Nakao K; Okumura Y; Sakakibara M; Okumura T; Tamura T; Miyamoto K
    Bioorg Med Chem; 2003 Sep; 11(18):3879-87. PubMed ID: 12927848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
    Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
    Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of equine mononuclear cell proliferation and leukotriene B4 synthesis by a specific 5-lipoxygenase inhibitor, A-63162.
    Olsen SC; Atluru D; Atluru S; McVey DS; Erickson HH
    Am J Vet Res; 1992 Jun; 53(6):1015-8. PubMed ID: 1320811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.